Laidlaw’s James Ahern Named to Crain’s New York Notable Leaders in Finance 2024

March 26th, 2024|

EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares

December 12th, 2023|

Laidlaw served as Co-Manager on the $129,000,000 Common Stock and Concurrent Private Placement for Soleno Therapeutics (SLNO)

December 5th, 2023|

Laidlaw acts as Co-Manager on the $287,500,000 Follow-On Offering for Viking Therapeutics.

March 31st, 2023|

Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.

December 19th, 2022|
Go to Top